Takeda Poised To Move Into Pharma Top 10 With Shire Combination

Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well. 

Ladder
Shire will climb into the pharma top 10 with Takeda deal • Source: Shutterstock

More from Deals

More from Business